Aug 25, 2026 07:37AM
Jul 15, 2026 08:45AM
May 12, 2026 04:15PM
Apr 28, 2026 07:12PM
Mar 3, 2026 04:15PM
Feb 25, 2026 07:19AM
Feb 25, 2026 07:18AM Vanda Pharmaceuticals Announces FDA Acceptance of Biologics License Application Filing for Imsidolimab for the Treatment of Generalized Pustular Psoriasis
Dec 19, 2025 09:06AM
Dec 15, 2025 07:01AM
Dec 15, 2025 07:00AM
Nov 4, 2025 04:15PM
Oct 1, 2025 01:20PM
Oct 1, 2025 01:13PM
Sep 30, 2025 06:48AM AnaptysBio (ANAB) PT Raised to $59 at H.C. Wainwright
Sep 29, 2025 04:07PM
Sep 29, 2025 04:05PM
Aug 6, 2025 04:15PM
May 5, 2025 04:15PM
Feb 28, 2025 12:26PM
Feb 27, 2025 04:15PM
Feb 3, 2025 07:30AM Vanda Pharmaceuticals (VNDA) and Anaptys (ANAB) Announce Exclusive Global License Agreement for Vanda to Develop and Commercialize Imsidolimab
Feb 3, 2025 07:30AM
Jan 6, 2025 10:35AM
Aug 5, 2024 04:15PM
May 9, 2024 04:12PM
May 9, 2024 04:10PM
May 9, 2024 04:05PM
Oct 9, 2023 08:02AM Anaptysbio (ANAB) Phase 3 Clinical Trial of Imsidolimab Met its Primary Endpoint
Oct 9, 2023 08:00AM
Aug 7, 2023 04:15PM
Jul 31, 2023 01:36PM
Jul 31, 2023 01:34PM
May 11, 2023 04:15PM
May 2, 2023 09:16AM
May 2, 2023 09:15AM AnaptysBio Announces British Journal of Dermatology Publication of Imsidolimab (IL-36R) Previously Reported Phase 2 GALLOP Data in Generalized Pustular Psoriasis (GPP)
May 2, 2023 09:15AM
Mar 28, 2023 05:49AM
Mar 27, 2023 06:50PM
Mar 27, 2023 06:50PM
Mar 1, 2023 04:05PM
Mar 1, 2023 04:05PM
Jan 5, 2023 04:08PM Anaptysbio (ANAB) Announces Portfolio Update
Jan 5, 2023 04:05PM
Jan 5, 2023 04:05PM
Dec 2, 2022 09:01AM
Dec 2, 2022 09:00AM
Dec 2, 2022 09:00AM
Nov 8, 2022 04:05PM
Nov 8, 2022 04:05PM AnaptysBio Announces Third Quarter 2022 Financial Results and Provides Pipeline Update
Sep 26, 2022 08:00AM

329,911 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All